跳至主要内容
临床试验/KCT0004042
KCT0004042招募中未知

Effect of RP-1701 on the Mild Cognitive Impairment for the Efficacy and Safety; A 12week, Multi-center, Randomized, Double-blind, Placebo-Controlled Clinical Trial

Kyung Hee University Hospital0 个研究点目标入组 100 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
招募中
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional Study

入排标准

年龄范围
55(Year) 至 85(Year)(—)
性别
All

入选标准

  • 1) Adult men and women aged from 55 t0 85 years old who complain memory loss
  • 2) Those who can decipher Korean
  • 3) CERAD-K memory score decreased from 1.0SD to less than 2.0SD compare to the same age and education level gruop (CERAD word list memory or word delayed recall or word recognition)
  • 4) A person who agrees to participate in the test and has signed an informed consent form

排除标准

  • 1) A person who is admitted to hospital with malignant tumor, severe cerebrovascular disease (cerebral infarction, cerebral hemorrhage, etc.), severe heart disease (unstable angina, myocardial infarction, arrhythmia requiring heart failure treatment) or 3 months after discharge
  • 2) A person with disease causing cognitive impairment such as dementia, Parkinson's disease,cerebral infarction etc.
  • 3) A person who has experience of administering drugs (antipsychotic drugs, degenerative disease agents, brain function improvers, tricyclic antidepressants) for dementia or other cognitive dysfunction within 4 weeks
  • 4) A person whose daily dose of vitamin E preparation is 400 IU or more, or whose dosage decreasing is inevitable.
  • 5) A person who have received estrogen replacement therapy (excluding topical application agents) within 2 months of the start of the test

研究者

发起方
Kyung Hee University Hospital

相似试验

Effect of RP-1701 on the Mild Cognitive Impairment... | 临床试验